Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9361387 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MEN1POLBMAPTKMT2A | |
| SCHEMBL9361350 | 0.92 | SLC16A3 (0.64) | ALDH1A1MEN1POLBMAPTKMT2A | |
| SCHEMBL9361358 | 0.92 | SLC16A3 (0.64) | ALDH1A1MEN1POLBMAPTKMT2A | |
| SCHEMBL22954004 | 0.92 | SLC16A3 (0.64) | ALDH1A1MEN1POLBMAPTKMT2A | |
| SCHEMBL15138635 | 0.91 | SLC16A3 (0.65) | ALDH1A1MEN1POLBMAPTKMT2A | |
| SCHEMBL18532822 | 0.90 | ALDH1A1 (0.53) | ALDH1A1MEN1POLBMAPTKMT2A | |
| SCHEMBL15138637 | 0.89 | SLC16A3 (0.64) | ALDH1A1MEN1POLBMAPTKMT2A | |
| SCHEMBL17831050 | 0.89 | SLC16A3 (0.64) | ALDH1A1MEN1POLBMAPTKMT2A | |
| SCHEMBL9772881 | 0.89 | SLC16A3 (0.64) | ALDH1A1MEN1POLBMAPTKMT2A | |
| SCHEMBL15132047 | 0.88 | MEN1 (0.76) | ALDH1A1MEN1POLBMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168083-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-06-16 | — | — | US | claimed |
| US-20140371272-A1 | THERAPEUTIC COMPOUNDS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2014-12-18 | — | — | US | claimed |
| EP-2804852-A2 | THERAPEUTIC COMPOUNDS | Regents Of The University Of Minnesota (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2013109972-A2 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-07-25 | — | — | WO | claimed |
| US-9573888-B2 | Therapeutic compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160168083-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-06-16 | — | — | US | disclosed |
| US-9296728-B2 | Therapeutic compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140371272-A1 | THERAPEUTIC COMPOUNDS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2014-12-18 | — | — | US | disclosed |
| EP-2804852-A2 | THERAPEUTIC COMPOUNDS | Regents Of The University Of Minnesota (US) | 2014-11-26 | — | — | EP | disclosed |
| WO-2013109972-A2 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-07-25 | — | — | WO | disclosed |
| EP-0335641-B1 | Organic nonlinear optical substance | TEIJIN LTD (JP) | 1994-01-05 | — | — | EP | disclosed |
| US-5196147-A | Optical crystals | TEIJIN LIMITED (JP) | 1993-03-23 | — | — | US | disclosed |
| EP-0335641-A2 | Organic nonlinear optical substance | TEIJIN LIMITED (JP) | 1989-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371272-A1 | THERAPEUTIC COMPOUNDS | HLA-DRB1, SLC10A1, NFATC1 | ALDH1A1 266/4885MEN1 28/4885POLB 4590/4885 |
| US-20160168083-A1 | THERAPEUTIC COMPOUNDS | HLA-DRB1, SLC10A1, NFATC1 | ALDH1A1 359/4885MEN1 30/4885POLB 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.